NanoViricides, Inc. will present at the PODD 2025 Conference on Monday, October 27, at 3 p.m. ET in Track 5A at the Westin Copley Hotel in Boston. President and Executive Chairman Anil R. Diwan, PhD, will provide updates on the company's antiviral drug pipeline and platform technologies available for licensing. The company's lead candidate, NV-387, is advancing toward Phase II trials for MPox and respiratory viral infections. Preclinical studies have demonstrated strong efficacy against respiratory syncytial virus (RSV), Influenza A, and Coronaviruses. This broad-spectrum approach represents a significant advancement in antiviral therapy, potentially addressing multiple viral threats with a single therapeutic platform.
NanoViricides' novel nanoviricide class of drug candidates and technology platform are based on intellectual property, technology, and proprietary know-how of TheraCour Pharma, Inc. The company has a Memorandum of Understanding with TheraCour for the development of drugs based on these technologies for all antiviral infections, though the agreement excludes cancer and similar diseases that may have viral origin but require different treatment approaches. The company's business model involves licensing technology from TheraCour Pharma Inc. for specific application verticals of specific viruses, as established at its foundation in 2005. NanoViricides holds broad, exclusive, sub-licensable field licenses to drugs developed in several licensed fields from TheraCour. Additional information about the company's technology and pipeline can be found at https://www.nanoviricides.com.
Beyond NV-387, the company is developing NV-HHV-1 for the treatment of Shingles and has programs targeting numerous other viral diseases including oral and genital Herpes, viral eye diseases, H1N1 swine flu, H5N1 bird flu, seasonal Influenza, HIV, Hepatitis C, Rabies, Dengue fever, and Ebola virus. The platform technology and programs are based on the TheraCour nanomedicine technology, which TheraCour licenses from AllExcel. NanoViricides maintains worldwide exclusive perpetual licenses for this technology for several drugs targeting specific human viral diseases, including HIV/AIDS, Hepatitis B and C, Rabies, Herpes Simplex Virus, Varicella-Zoster Virus, Influenza, Asian Bird Flu, Dengue viruses, Japanese Encephalitis virus, West Nile Virus, Ebola/Marburg viruses, and certain Coronaviruses. The company intends to obtain additional licenses for RSV, Poxviruses, and/or Enteroviruses if initial research proves successful.
The company acknowledges the inherent risks in pharmaceutical development, noting that the path to typical drug development is extremely lengthy and requires substantial capital. As with any drug development efforts, there can be no assurance that any of the company's pharmaceutical candidates will show sufficient effectiveness and safety for human clinical development, nor that successful laboratory results against coronavirus will lead to successful clinical trials or commercial products. Investors can access the latest news and updates relating to NNVC through the company's newsroom at https://ibn.fm/NNVC.
